Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Permissions Requests - Help - - Sign up - Phone number 902 888 740

2017 FI

© Thomson Reuters, Journal Citation Reports, 2017

Indexed in:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME Cancerlit, Bibliomed, CabHealth, Scisearch, HealthStar, Scopus, Prous, Science Intergews, Science Citation Index Expanded.


  • Impact Factor: 1.644 (2017)
  • CiteScore 2017: 1.24
    Read more
  • SCImago Journal Rank (SJR):0,504
  • Source Normalized Impact per Paper (SNIP):0,791

© Clarivate Analytics, Journal Citation Reports 2017

Allergol Immunopathol (Madr) 2013;41:73-85 - DOI: 10.1016/j.aller.2012.03.001
Original article
The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis
J. Mallola,??, , J. Craneb, E. von Mutiusc, J. Odhiambod, U. Keile, A. Stewartf, the ISAAC Phase Three Study Group
a Department of Paediatric Respiratory Medicine, Hospital CRS El Pino, University of Santiago de Chile (USACH), Chile
b Wellington Asthma Research Group, Wellington School of Medicine, New Zealand
c Dr von Haunerschen Kinderklinik de Universität München, Germany
d Centre Respiratory Diseases Research Unit, Kenya Medical Research Institute, Nairobi, Kenya
e Institut für Epidemiologie und Sozialmedizin, Universität Münster, Germany
f Epidemiology and Biostatistics, School of Population Health, The University of Auckland, New Zealand
Received 12 February 2012, Accepted 10 March 2012

This ISAAC Phase Three synthesis provides summarised information on the main findings of the study, regional tables and figures related to the prevalence and severity of current symptoms of asthma, rhinoconjunctivitis and eczema in the main regions of the world. The large number of surveyed children (≈1,200,000), the large number of centres (233) and countries (98) that participated in ISAAC Phase Three makes this study the most comprehensive survey of these diseases ever undertaken. Globally, the prevalence for current asthma, rhinoconjunctivitis and eczema in the 13–14-year age group was 14.1%, 14.6% and 7.3%, respectively. In the 6–7-year age group the prevalence for current asthma, rhinoconjunctivitis and eczema was 11.7%, 8.5% and 7.9%, respectively. The study shows a wide variability in the prevalence and severity of asthma, rhinoconjunctivitis and eczema which occurs not just between regions and countries but between centres in the same country and centres in the same city. This study definitively establishes that the prevalence of those diseases can be very high in non-affluent centres with low socioeconomic conditions. The large variability also suggests a crucial role of local environment characteristics to determine the differences in prevalence between one place and another. Thus, ISAAC Phase Three has provided a large body of epidemiological information on asthma, rhinoconjunctivitis and eczema in childhood from contrasting environments which is expected to yield new clues about the aetiology of those conditions and reasons for their marked global variability.

Asthma, Rhinitis, Eczema, ISAAC, Children
Download PDF


Read the complete contents of this article

Already registered?